Cancer Treatment Reviews
Volume 29 , Pages 21-31 , May 2003

Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib

  • James C. Cusack

      Affiliations

    • Corresponding Author InformationCorrespondence to: James C. Cusack, Jr, MD, Harvard Medical School, Massachusetts General Hospital Boston, MA 02114, USA. Tel.: +1-617-724-4093; fax: +1-617-724-3895

References 

  1. Adams J, Palombella VJ, Sausville EA, et al.  Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59(11):2615–2622
  2. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res. 1999;5(9):2638–2645
  3. Hideshima T, Richardson P, Chauhan D, et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61(7):3071–3076
  4. Ma MH, Parker KM, Manyak S, et al.  Proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma cells to chemotherapeutic agents and overcomes chemoresistance through inhibition of the NF-κB pathway. Blood. 2001;98(11):437a
  5. Steiner P, Neumeier H, Lightcap ES, et al.  Generation of PS-341-adapted human multiple myeloma cells as experimental tools for analysis of proteasome function in cancer. Blood. 2001;98(11):310a
  6. Feinman R, Gangurde P, Miller S, et al.  Proteasome inhibitor PS-341 inhibits constitutive NF-κB activation and bypasses the anti-apoptotic bcl-2 signal in human multiple myeloma cells. Blood. 2001;98(11):640a
  7. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J. Surg. Res. 2001;100(1):11–17
  8. Shah SA, Potter MW, McDade TP, et al.  26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J. Cell Biochem. 2001;82(1):110–122
  9. Cusack JC, Liu R, Houston M, et al.  Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-κB inhibition. Cancer Res. 2001;61(9):3535–3540
  10. Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin. Cancer Res. 2000;6(9):3719–3728
  11. Neumeier H, Hoar, K, Pink, M, et al. Hypoxia increases potency of the proteasome inhibitor VELCADE (TM) (bortezomib) for injection: potential for a hypoxic cell cytotoxin in solid tumors. Presented at the EORTC-NCI-AACR Conference on Molecular Targets and Cancer Therapeutics; Frankfurt, Germany, November 19–22, 2002
  12. Pervan M, Pajonk F, Sun JR, Withers HR, McBride WH. Molecular pathways that modify tumor radiation response. Am. J. Clin. Oncol. 2001;24(5):481–485
  13. Russo SM, Tepper JE, Baldwin AS, et al.  Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-κB. Int. J. Radiat. Oncol. Biol. Phys. 2001;50(1):183–193
  14. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J. Clin. Invest. 2001;107(3):241–246
  15. Spencer E, Jiang J, Chen ZJ. Signal-induced ubiquitination of IκBα by the F-box protein Slimb/β-TrCP. Genes Dev. 1999;13(3):284–294
  16. Alkalay I, Yaron A, Hatzubai A, Orian A, Ciechanover A, Ben Neriah Y. Stimulation-dependent IκBα phosphorylation marks the NF-κB inhibitor for degradation via the ubiquitin–proteasome pathway. Proc. Natl. Acad. Sci. USA. 1995;92(23):10599–10603
  17. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91(1):3–21
  18. Ni H, Ergin M, Huang Q, et al.  Analysis of expression of nuclear factor kappa B (NF-κB) in multiple myeloma: downregulation of NF-κB induces apoptosis. Br. J. Haematol. 2001;115(2):279–286
  19. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998;281(5383):1680–1683
  20. Chen C, Edelstein LC, Gelinas C. The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-x (L). Mol. Cell. Biol. 2000;20(8):2687–2695
  21. Ogata A, Chauhan D, Teoh G, et al.  IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J. Immunol. 1997;159(5):2212–2221
  22. Chauhan D, Pandey P, Ogata A, et al.  Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene. 1997;15(7):837–843
  23. Palombella VJ, Conner EM, Fuseler JW, et al.  Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis. Proc. Natl. Acad. Sci. USA. 1998;95(26):15671–15676
  24. An B, Goldfarb RH, Siman R, Dou QP. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ. 1998;5(12):1062–1075
  25. Masdehors P, Merle-Beral H, Magdelenat H, Delic J. Ubiquitin–proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic death activation. Leuk. Lymphoma. 2000;38(5-6):499–504
  26. Delic J, Masdehors P, Omura S, et al.  The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-α-initiated apoptosis. Br. J. Cancer. 1998;77(7):1103–1107
  27. LeBlanc R, Catley L, Hideshima T, Pien CS, Elliott PJ, Anderson KC. Proteasome inhibitor PS-341 inhibits human multiple myeloma cell growth in a murine model. Blood. 2001;98(11):774a
  28. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ, Sledge GW. Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol. Cell. Biol. 1997;17(7):3629–3639
  29. Sovak MA, Bellas RE, Kim DW, et al.  Aberrant nuclear factor-κB/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest. 1997;100(12):2952–2960
  30. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD. Constitutive activation of IκB kinase α and NF-κB in prostate cancer cells is inhibited by ibuprofen. Oncogene. 1999;18(51):7389–7394
  31. Patel NM, Nozaki S, Shortle NH, et al.  Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide. Oncogene. 2000;19(36):4159–4169
  32. Bours V, Dejardin E, Goujon-Letawe F, Merville MP, Castronovo V. The NF-κB transcription factor and cancer: high expression of NF-κB- and IκB-related proteins in tumor cell lines. Biochem. Pharmacol. 1994;47(1):145–149
  33. Reuning U, Wilhelm O, Nishiguchi T, et al.  Inhibition of NF-κB-Rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1. Nucleic Acids Res. 1995;23(19):3887–3893
  34. Grundker C, Schulz K, Gunthert AR, Emons G. Luteinizing hormone-releasing hormone induces nuclear factor κB-activation and inhibits apoptosis in ovarian cancer cells. J. Clin. Endocrinol. Metab. 2000;85(10):3815–3820
  35. Lind DS, Hochwald SN, Malaty J, et al.  Nuclear factor-κB is upregulated in colorectal cancer. Surgery. 2001;130(2):363–369
  36. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin. Cancer Res. 1999;5(1):119–127
  37. Arlt A, Vorndamm J, Breitenbroich M, et al.  Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene. 2001;20(7):859–868
  38. Arlt A, Vorndamm J, Muerkoster S, et al.  Autocrine production of interleukin 1β confers constitutive nuclear factor κB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res. 2002;62(3):910–916
  39. Mukhopadhyay T, Roth JA, Maxwell SA. Altered expression of the p50 subunit of the NF-κB transcription factor complex in non-small cell lung carcinoma. Oncogene. 1995;11(5):999–1003
  40. Duffey DC, Chen Z, Dong G, et al.  Expression of a dominant-negative mutant inhibitor-κBα of nuclear factor-κB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res. 1999;59(14):3468–3474
  41. Sunwoo JB, Chen Z, Dong G, et al.  Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-κB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. 2001;7(5):1419–1428
  42. Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res. 1996;56(11):2649–2654
  43. Chadebech P, Brichese L, Baldin V, Vidal S, Valette A. Phosphorylation and proteasome-dependent degradation of Bcl-2 in mitotic-arrested cells after microtubule damage. Biochem. Biophys. Res. Commun. 1999;262(3):823–827
  44. Cayrol C, Ducommun B. Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21. Oncogene. 1998;17(19):2437–2444
  45. Pagano M, Tam SW, Theodoras AM, et al.  Role of the ubiquitin–proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 1995;269(5224):682–685
  46. Salvat C, Jariel-Encontre I, Acquaviva C, Omura S, Piechaczyk M. Differential directing of c-Fos and c-Jun proteins to the proteasome in serum-stimulated mouse embryo fibroblasts. Oncogene. 1998;17(3):327–337
  47. Clurman BE, Sheaff RJ, Thress K, Groudine M, Roberts JM. Turnover of cyclin E by the ubiquitin–proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev. 1996;10(16):1979–1990
  48. Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin–proteasome pathway. Genes Dev. 1997;11(8):957–972
  49. Sudakin V, Ganoth D, Dahan A, et al.  The cyclosome, a large complex containing cyclin-selective ubiquitin ligase activity, targets cyclins for destruction at the end of mitosis. Mol. Biol. Cell. 1995;6(2):185–197
  50. Buschmann T, Fuchs SY, Lee CG, Pan ZQ, Ronai Z. SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53. Cell. 2000;101(7):753–762
  51. Gorlick R, Bertino JR. Drug resistance in colon cancer. Semin. Oncol. 1999;26(6):606–611
  52. Dietrich C, Bartsch T, Schanz F, Oesch F, Wieser RJ. p53-Dependent cell cycle arrest induced by N-acetyl-l-leucinyl-l-leucinyl-l-norleucinal in platelet-derived growth factor-stimulated human fibroblasts. Proc. Natl. Acad. Sci. USA. 1996;93(20):10815–10819
  53. Eilers M, Schirm S, Bishop JM. The MYC protein activates transcription of the α-prothymosin gene. EMBO J. 1991;10(1):133–141
  54. Saint-Ruf C, Gerbault-Seureau M, Viegas-Pequignot E, Zafrani B, Cassingena R, Dutrillaux B. Proto-oncogene amplification and homogeneously staining regions in human breast carcinomas. Genes. Chromosomes Cancer. 1990;2(1):18–26
  55. Marcu KB, Bossone SA, Patel AJ. myc Function and regulation. Annu. Rev. Biochem. 1992;61:809–860
  56. Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M, Dang CV. Tumor growth inhibition induced in a murine model of human Burkitt’s lymphoma by a proteasome inhibitor. Cancer Res. 1998;58(19):4342–4348
  57. Bold RJ, Chandra J, McConkey DJ. Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann. Surg. Oncol. 1999;6(3):279–285
  58. Ihde DC. Chemotherapy of lung cancer. N. Engl. J. Med. 1992;327(20):1434–1441
  59. Bergh JC. Gene amplification in human lung cancer. The myc family genes and other proto-oncogenes and growth factor genes. Am. Rev. Respir. Dis. 1990;142(6 Pt 2):S20–S26
  60. Huang Y, Johnson KR, Norris JS, Fan W. Nuclear factor-κB/IκB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res. 2000;60(16):4426–4432
  61. Wang CY, Cusack JC, Liu R, Baldwin ASJ. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat. Med. 1999;5(4):412–417
  62. Tabata M, Tabata R, Grabowski DR, Bukowski RM, Ganapathi MK, Ganapathi R. Roles of NF-κB and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human nonsmall cell lung carcinoma. J. Biol. Chem. 2001;276(11):8029–8036
  63. Cusack JC, Liu R, Baldwin AS. NF-kB and chemoresistance: potentiation of cancer chemotherapy via inhibition of NF-kB. Drug Resist. Update. 1999;2:271–273
  64. Das KC, White CW. Activation of NF-κB by antineoplastic agents. Role of protein kinase C. J. Biol. Chem. 1997;272(23):14914–14920
  65. Cusack JC, Liu R, Baldwin AS. Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-κB activation. Cancer Res. 2000;60(9):2323–2330
  66. Hideshima T, Chauhan D, Richardson P, et al.  NF-κB as a therapeutic target in multiple myeloma. J. Biol. Chem. 2002;277(19):16639–16647
  67. Mitsiades N, Mitsiades CS, Poulaki V, et al.  Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl. Acad. Sci. USA. 2002;99(22):14374–14379
  68. Li B, Dou QP. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc. Natl. Acad. Sci. USA. 2000;97(8):3850–3855
  69. Dong QG, Sclabas GM, Fujioka S, et al.  The function of multiple IκB:NF-κB complexes in the resistance of cancer cells to taxol-induced apoptosis. Oncogene. 2002;21(42):6510–6519
  70. Jones DR, Broad RM, Comeau LD, Parsons SJ, Mayo MW. Inhibition of nuclear factor κB chemosensitizes non-small cell lung cancer through cytochrome c release and caspase activation. J. Thorac. Cardiovasc. Surg. 2002;123(2):310–317
  71. Desai SD, Li TK, Rodriguez-Bauman A, Rubin EH, Liu LF. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res. 2001;61(15):5926–5932
  72. Ogiso Y, Tomida A, Lei S, Omura S, Tsuruo T. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res. 2000;60(9):2429–2434
  73. Mimnaugh EG, Chen HY, Davie JR, Celis JE, Neckers L. Rapid deubiquitination of nucleosomal histones in human tumor cells caused by proteasome inhibitors and stress response inducers: effects on replication, transcription, translation, and the cellular stress response. Biochemistry. 1997;36(47):14418–14429
  74. Mimnaugh EG, Yunmbam MK, Li Q, et al.  Prevention of cisplatin–DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors. Biochem. Pharmacol. 2000;60(9):1343–1354
  75. Li QQ, Ding L, Reed E. Proteasome inhibition suppresses cisplatin-dependent ERCC-1 mRNA expression in human ovarian tumor cells. Res. Commun. Mol. Pathol. Pharmacol. 2000;107(5-6):387–396
  76. Adams J, Palombella VJ, Elliott PJ. Proteasome inhibition: a new strategy in cancer treatment. Invest. New Drugs. 2000;18(2):109–121
  77. Wu Y, Luo H, Kanaan N, Wu J. The proteasome controls the expression of a proliferation-associated nuclear antigen Ki-67. J. Cell Biochem. 2000;76(4):596–604
  78. Donzelli M, Squatrito M, Ganoth D, Hershko A, Pagano M, Draetta GF. Dual mode of degradation of Cdc25 A phosphatase. EMBO J. 2002;21(18):4875–4884
  79. Chen F, Zhang Z, Bower J, et al.  Arsenite-induced Cdc25C degradation is through the KEN-box and ubiquitin–proteasome pathway. Proc. Natl. Acad. Sci. USA. 2002;99(4):1990–1995
  80. Jesenberger V, Jentsch S. Deadly encounter: ubiquitin meets apoptosis. Nat. Rev. Mol. Cell. Biol. 2002;3(2):112–121
  81. Orlowski RZ. The role of the ubiquitin–proteasome pathway in apoptosis. Cell Death Differ. 1999;6(4):303–313
  82. Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer. 2002;2(4):301–310

PII: S0305-7372(03)00079-3

doi: 10.1016/S0305-7372(03)00079-3

Cancer Treatment Reviews
Volume 29 , Pages 21-31 , May 2003

Article Tools

* Image Usage & Resolution